Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.40 |
| ▸ | PGR | P06401 | 8/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562403 | 1.00 | BACE1 (0.40) | BACE1CYP3A4PGRCYP2D6AR | |
| SCHEMBL12191208 | 0.88 | BACE1 (0.44) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7601138 | 0.88 | BACE1 (0.44) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8202956 | 0.88 | BACE1 (0.41) | BACE1CYP3A4PGRCYP2D6AR | |
| SCHEMBL7604899 | 0.88 | BACE1 (0.41) | BACE1CYP3A4PGRCYP2D6AR | |
| SCHEMBL14105852 | 0.88 | BACE1 (0.33) | BACE1CYP3A4 | |
| SCHEMBL7600773 | 0.87 | BACE1 (0.36) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12191193 | 0.87 | BACE1 (0.36) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8207715 | 0.85 | CYP3A4 (0.33) | BACE1CYP3A4PGR | |
| SCHEMBL12190945 | 0.85 | BACE1 (0.42) | BACE1CYP3A4PGRCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885CYP3A4 853/4885PGR 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.